Uses
For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.
Source: US FDA prescribing information
Fixed-dose combination
Brompheniramine, Dextromethorphan and Pseudoephedrine is a fixed-dose combination of a sigma-1 agonist, an uncompetitive N-methyl-D-aspartate receptor antagonist and an alpha-adrenergic agonist. It is available as syrup and oral solution. MedsAcross supplies Brompheniramine, Dextromethorphan and Pseudoephedrine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.
Source: US FDA prescribing information
Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to under 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (½ teaspoonful) every 4 hours. Infants 6 months to under 2 years of age: Dosage to be established by a physician. Do not exceed 6 doses during a 24-hour period.
Source: US FDA prescribing information
Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase (MAOI) inhibitors. Antihistamines should not be used to treat lower respiratory tract conditions including asthma.
Source: US FDA prescribing information
Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions, and death. Antihistamines may diminish mental alertness. In the young child, they may produce excitation.
Source: US FDA prescribing information
The most frequent adverse reactions to brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup are: sedation, dryness of mouth, nose and throat, thickening of bronchial secretions, dizziness. Other adverse reactions may include: Dermatologic: Urticaria, drug rash, photosensitivity, pruritus. Cardiovascular System: Hypotension, hypertension, cardiac arrhythmias, palpitation. CNS: Disturbed coordination, tremor, irritability, insomnia, visual disturbances, weakness, nervousness, convulsions, headache, euphoria, and dysphoria. G.U. System: Urinary frequency, difficult urination. G.I. System: Epigastric discomfort, anorexia, nausea, vomiting, diarrhea, constipation. Respiratory System: Tightness of chest and wheezing, shortness of breath. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.
Source: US FDA prescribing information
Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup and MAO inhibitors should be avoided. Central nervous system (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Brompheniramine, Dextromethorphan and Pseudoephedrine, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Brompheniramine, Dextromethorphan and Pseudoephedrine 2 mg/10 mg/30 mg per 5 mL syrupOralGeneric name | Brompheniramine, Dextromethorphan and Pseudoephedrine | — | US FDA | Available on request |
| Brompheniramine, Dextromethorphan and Pseudoephedrine 2 mg/10 mg/30 mg per 5 mL oral solutionOralGeneric name | Brompheniramine, Dextromethorphan and Pseudoephedrine | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 24 August 1984 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 2 presentations of Brompheniramine, Dextromethorphan and Pseudoephedrine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Brompheniramine, Dextromethorphan and Pseudoephedrine on 24 August 1984, according to Drugs@FDA.
No listed presentation of Brompheniramine, Dextromethorphan and Pseudoephedrine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.